Your AI-Trained Oncology Knowledge Connection!

Patrick Boland, MD

home / authors / patrick-boland-md

Articles

Patrick Boland, MD

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Patrick Boland, MD
November 22nd 2023

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

Read More

Patrick Boland, MD

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

Patrick Boland, MD
December 7th 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Read More

Patrick Boland, MD

Dr. Boland on Determining When to Utilize Up-front Perioperative Chemotherapy in CRC

Patrick Boland, MD
December 6th 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

Read More

Patrick Boland, MD

Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC

Patrick Boland, MD
November 5th 2021

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Read More

Latest Updated Articles

RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2 expert is featured in this series.
Published: December 24th 2024 | Updated: January 28th 2025
Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: January 16th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show